BMJ:产前糖皮质激素暴露或使早产儿获益

2017-04-25 吴星 环球医学

在既往通过出生时胎龄分析的产前糖皮质激素的随机对照试验的荟萃分析中,30~34周妊娠出生的早产儿亚组中死亡率降低,而非妊娠30周前出生的亚组。2017年3月,发表在《BMJ》的一项由美国科学家进行的前瞻性队列研究,考察了产前任何糖皮质激素暴露与早产儿结局的相关性。



在既往通过出生时胎龄分析的产前糖皮质激素的随机对照试验的荟萃分析中,30~34周妊娠出生的早产儿亚组中死亡率降低,而非妊娠30周前出生的亚组。2017年3月,发表在《BMJ》的一项由美国科学家进行的前瞻性队列研究,考察了产前任何糖皮质激素暴露与早产儿结局的相关性。

目的:考察按照目前的推荐,产前任何糖皮质激素暴露是否与各胎龄新生儿死亡率降低相关。

设计:前瞻性队列研究。

地点:美国Pediatrix医疗集团300所新生儿重症监护室(ICU)。

受试者:2009年1月1日至2013年12月31日期间出生的117941例胎龄在23 0/7至34 6/7周的新生儿。

暴露:任何产前糖皮质激素暴露。

主要结局测量指标:通过胎龄、产前糖皮质激素暴露,以及校正出生体重、性别、分娩方式和多胎出生的模型分析的死亡或重大在院发病。

结果:与产前没有糖皮质激素暴露相比,产前暴露于糖皮质激素的29周或不足29周、31周和33~34周各胎龄新生儿(n=81832)死亡率显着较低(校正比值比0.32~0.55)。需要使用产前糖皮质激素,预防出院前1例死亡的例数从23~24周的6例增加至34周的798例。在极低胎龄产前暴露于糖皮质激素的新生儿,无重大在院发病生存率较高。与小于30周各胎龄,以及胎龄在30周或更长出生的新生儿的大部分胎龄,没有糖皮质激素暴露的新生儿相比,产前暴露于糖皮质激素的新生儿,严重颅内出血或死亡、坏死性结肠炎2期及以上或死亡,以及严重早产儿视网膜病或死亡的发生率较低。

结论:在23~34周胎龄出生的新生儿中,与没有暴露相比,产前暴露于糖皮质激素与大部分胎龄较低的发病率和死亡率相关。产前暴露于糖皮质激素对死亡率的影响似乎在极低胎龄的新生儿中最明显。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848292, encodeId=241b184829219, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Feb 06 03:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701156, encodeId=a8141e01156ad, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue Oct 31 22:01:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502501, encodeId=ce92150250118, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600263, encodeId=92521600263f0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190502, encodeId=1aa019050273, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Apr 25 16:54:28 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2018-02-06 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848292, encodeId=241b184829219, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Feb 06 03:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701156, encodeId=a8141e01156ad, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue Oct 31 22:01:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502501, encodeId=ce92150250118, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600263, encodeId=92521600263f0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190502, encodeId=1aa019050273, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Apr 25 16:54:28 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848292, encodeId=241b184829219, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Feb 06 03:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701156, encodeId=a8141e01156ad, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue Oct 31 22:01:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502501, encodeId=ce92150250118, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600263, encodeId=92521600263f0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190502, encodeId=1aa019050273, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Apr 25 16:54:28 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-27 qilu_qi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848292, encodeId=241b184829219, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Feb 06 03:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701156, encodeId=a8141e01156ad, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue Oct 31 22:01:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502501, encodeId=ce92150250118, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600263, encodeId=92521600263f0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190502, encodeId=1aa019050273, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Apr 25 16:54:28 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1848292, encodeId=241b184829219, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Feb 06 03:01:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701156, encodeId=a8141e01156ad, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Tue Oct 31 22:01:00 CST 2017, time=2017-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502501, encodeId=ce92150250118, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600263, encodeId=92521600263f0, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Thu Apr 27 06:01:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190502, encodeId=1aa019050273, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Tue Apr 25 16:54:28 CST 2017, time=2017-04-25, status=1, ipAttribution=)]
    2017-04-25 三生有幸9135

    学习一下谢谢分享

    0

相关资讯

The Lancet:BDP/FF/GB三联制剂对COPD病情控制效果更佳

对于症状性,FEV1小于50%并有恶化历史的慢性阻塞性肺病患者,使用BDP/FF/GB三联超细粉混合制剂较单独使用格隆溴铵对病情控制更为有效

Crit Care:感染性休克患者不同种糖皮质激素治疗有差异吗?

由此可见,没有明确的证据表明任何一个皮质激素药物或治疗方案可能会比其他治疗更有效在降低死亡率、减少胃肠道出血或感染性休克二重感染方面。氢化可的松静脉注射或输液可能比安慰剂和甲基强的松龙更容易导致休克逆转。

Br J Clin Pharmacol:震惊!吸入类固醇可增加哮喘患者肺炎的发生风险

既往研究表明吸入糖皮质激素(ICS)可增加COPD患者肺炎的发生风险,但是是否会增加哮喘患者肺炎的发生风险目前尚未清楚。,本研究旨在探究ICS是否会增加12-35岁哮喘患者肺炎的发生风险。研究人员使用1990-2007年魁北克健康保险数据库的资料共纳入了152412名研究对象。结果随访期间1928名参与者发生肺炎。分析数据发现当前ICS的使用与肺炎的发生风险相关(RR 1.83;95% CI 1.

CHEST: COPD急性加重患者嗜酸粒细胞与再入院几率增加相关

COPD亚群患者显示组织或血液中有嗜酸粒细胞性炎症。以往研究中有关嗜酸粒细胞水平的增加与低的再入院结果相矛盾。本研究的目标是通过随访嗜酸粒细胞水平升高的重度COPD急性加重患者,研究血液中高嗜酸粒细胞水平与不良临床结局之间的相关性。

Crit Care:社区获得性肺炎患者糖皮质激素与不良结局之间存在时间依赖相关性!

在不同的糖皮质激素中,皮质醇表现出与CAP的死亡率相关性最高。而入院时更为明显的糖皮质激素应激反应与较高的短期不良结局相关,这些患者的长期结局是有利的。

Oncotarget:吸入性糖皮质激素能预防肺癌发生?

近期,Oncotarget杂志中一篇文章报道:使用吸入性糖皮质激素(ICS)治疗COPD的同时,也有助于预防肺癌的发生。该研究者在全国进行了一项以人群为基础的队列研究,从台湾全民健康保险数据库中提取了13686名COPD女性的患者(ICS使用者,N=1290;未使用ICS,N=12396)的资料,这些患者均是在1997-2009期间确诊为COPD。对这些患者进行随访直到2011年,对肺癌的发病率进